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Objective. A number of evidence-based guidelines for diagnosis and management of prostate cancer have been published. The
aim of this study is to evaluate the adherence of Italian urologists to the guidelines concerning the preoperative imaging staging
of prostate cancer. Methods. In October 2007 a multicentric observational perspective study called Multicentric Italian Report on
Radical prostatectomy Outcome and Research (MIRROR) was started in 135 Italian urology centers. Recruitment was closed in
December 2008 and 2,408 cases were collected. In this paper we have taken into consideration all examinations carried out for
preoperative imaging staging, evaluating compliance with the recommendations in the American Urological Association (AUA)
and European Association of Urology (EAU) guidelines. Results. Five hundred sixty-seven (53.34%) patients were not managed
according to the EAU guidelines concerning T-staging, 545 (51.27%) concerning N-staging and 757 (71.21%) concerning M-
staging. According to AUA guidelines, we also analyzed patients with a Gleason grade of biopsy specimens of 7: 238 (57.35%) of
these patients had undergone testing for T staging, 244 (57.35%) for N-staging and 322 (77.60%) for M-staging. Conclusions. The
compliance of Italian urologists with the guidelines is low, leading to an inappropriate increase in cost of care and unnecessary
anxiety for the patients.
1. Introduction
Radical prostatectomy (RP) is an operation which is rou-
tinely performed in all Italian urology centers; the indications
for this operation vary, and the preoperative workup may
also vary from center to center and according to the stage
of the disease.
The American Urological Association (AUA) and the
European Association of Urology (EAU) have set up, and
frequently review, the guidelines to provide urologists with
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an evidence-based pathway to diagnosis and management of
prostate cancer. Concerning the AUA guidelines [1], there
are no specific indications concerning imaging for patients
undergoing radical prostatectomy.
The PSA best practice statement of the AUA guidelines
[2] reports that routine imaging staging and bone scans are
not necessary in every case of diagnosed prostate cancer.
In particular, imaging is thought unnecessary if the PSA is
<25 ng/mL and bone scans are not recommended when PSA
is <20 ng/mL.
The EAU guidelines on prostate cancer were first pub-
lished in 2001 [3] and since then have undergone several
updates, up to the latest version in 2011 that can also
be downloaded online [4]. According to EAU guidelines,
[4] local staging (T-staging) should be based on findings
from digital rectal examination (DRE) and in very specific
cases from magnetic resonance imaging (MRI), even if the
literature shows a wide range in the accuracy of T-staging
by MRI, from 50–92% [4]. The assessment of lymph-node
status (N-staging) can be avoided in patients with stage T2
or less, PSA < 20 ng/mL and a Gleason score ≤6, as they have
less than a 10% likelihood of having node metastases.
A bone scan to rule out skeletal metastases may not be
appropriate in asymptomatic patients if the serum PSA level
is less than 20 ng/mL in the presence of well or moderately
diﬀerentiated tumors. The purpose of the guidelines is not to
prescribe how a clinician should treat a patient, but rather
to provide a guide and an authoritative reference on the
most appropriate diagnostic pathway currently available. It
is expected that the majority of urologists will incorporate
the guideline recommendations into clinical practice. To our
knowledge, there are few articles that discuss the proportion
of patients receiving appropriate use of imaging for CaP,
none of them consider Italian population [5–9]. In the
present work, we attempted to assess the adherence to these
guidelines in several Italian urology centers.
2. Material and Methods
An independent multicenter perspective observational study
called MIRROR (Multicenter Italian Report on Radical
prostatectomy Outcome and Research) was begun in Italy
in October 2007 with the aim of creating a register of the
radical prostatectomies carried out, independently of the
surgical technique used, collecting as many data as possible
on a digital electronic Case Report Form (e-CRF) held by
an independent third party Clinical Research Organization
(CRO) Clicon srl of Reggio Emilia, Italy. The study was
promoted by Leading Urological No profit foundation
Advanced research (LUNA), the research foundation of the
Italian Urological Association (SIU) which supported the
study with an unrestricted grant.
The study involved 135 Italian centers which enrolled
2,408 consecutive patients who were chosen for and then
submitted to radical prostatectomy. All the data were blind-
recorded and stored in a web data base.
To ensure the standardization of this data collection, each
center was provided with the same e-CRF. All data were
stored in eXtensible Markup Language (XML) data files that
were sent to the data server, recorded in a MicroSoft Struc-
tured Query Language (MS-SQL) database, and analyzed
by a centralized data manager. The recruiting centers were
either high-volume institutes or small community hospitals
with a low number of radical prostatectomies per year, which
enrolled only few patients. The average number of patients
treated in each center was 35 with a range from 2 to 186. In
this paper, we have taken into account the tests carried out for
staging during preoperative evaluation in the various centers
and correlated them with the recommendations of the AUA
and EAU guidelines. According to EAU guidelines, patients
with PSA <20 and Gleason score <6 can avoid preoperative
imaging staging. The AUA guidelines, on the other hand, say
that imaging staging is unnecessary if the PSA is <20 ng/mL
and Gleason score is <7.
3. Results
We identified 1,288 patients overall with PSA <20 and
Gleason score <6. Among these, we were able to evaluate
1,063 patients. As far as the other 225 patients concern,
we do not have data concerning on preoperative staging
so we excluded them from the analysis. The average age
was 63.2 ± 6.5 years (median 62), ranging from 43 to 74.
Preoperative PSA was 6.5± 7.2 ng/mL, median 5,8 g/mL. All
patients undergone DRE and as regards the clinical stages,
956 patients were classified as T1 (89.9%) and 107 as T2
(10.1%). Preoperative prostate needle biopsy was performed
transperineally in 307 (28.9%) patients and transrectally in
756 (71.1%). The Gleason grade of biopsy specimens was
4 in 34 patients (3.19%), 5 in 121 (11.38%), and 6 in
908 (85.42%). A centralized pathological review was not
performed. The patients’ characteristics are summarized in
Table 1.
567 patients (53.34%) were not managed according
to the guidelines concerning T-staging, and 545 (51.27%)
patients were not managed according to the guidelines
concerning N-staging. The most frequently performed test
was an abdominal CT. Finally, 757 (71.21%) patients under-
went a bone scan and, therefore, M-staging which is not
recommended by the guidelines for this subset of patients.
As prescribed by AUA guidelines, we also analyzed
patients with a Gleason grade of biopsy of 7. The average age
of these patients was 65,4 ± 6,4 years (median 67), ranging
from 41 to 77. Preoperative PSA was 7,7 ± 3,95 ng/mL,
mediana 8,2 ng/mL. (Table 2). Among those 415 patients,
238 (57,35%) underwent testing for T staging and 244
(57,35%) for N-staging. Also in this subgroup of patients
the most frequently performed test was an abdominal CT.
322 patients (77,60%) underwent a bone scan for M-staging.
(Table 3). If we consider all patients with PSA ≤20 and
Gleason ≤ to 7 overall, more than 50% of the patients
underwent unnecessary testing for T- and N-staging and
more than 70% for M-staging (Table 3, Figure 1).
As showed in Table 4, we did not report any significant
diﬀerence in the use by Italian urologists of imaging proce-
dures for TNM staging between EAU and AUA guidelines.
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Table 1: Clinical data and preoperative characteristics of the 1,063 patients.
Clinical data
Age (mean ± SD/range) 63.2 ± 6.5 (43–74)
BMI (mean ± SD/range) 26.5 ± 3.0 (19.2–33.0)
Preoperative characteristics
PSA (mean ± SD/range) 6.5 ± 7.2 (2.2–18.7)
Clinical stage no. (%)
cT0-cT1c 956 (89.9%)
cT2 107 (10.1%)
Biopsy technique no. (%)
transperineal 307 (28.9%)
transrectal 756 (71.1%)
Gleason grade of biopsy no. (%)
4 34 (3.19%)
5 121 (11.38%)
6 908(85.42%)
Table 2: Clinical data and preoperative characteristics of the three groups of patients.
Gleason ≤ 6 Gleason = 7 Gleason ≤ 7
AGE
(mean ± SD/range; median) 63.2± 6.5 (43–74); 62 65.4± 6.4 (41–77); 67 64.3± 6.4 (41–77); 64
PSA
(mean ± SD/range; median) 6.5± 7.2 (2.2–18.7); 5,8 7.7± 3.95 (0.13–19.66); 8,2 7.83± 3.74 (0.13–19.66); 9,8
CLINICAL STAGE
cT1a-cT1c 956 (89.8%) 159 (38.3%) 1115 (75.4%)
cT2 107 (10.2%) 256 (61.7%) 363 (24,6%)
SURGERY
RRP 865 (81.4%) 324 (77.97%) 1189 (80.4%)
ROB 136 (12.8%) 61 (14.77%) 197 (13.3%)
LAP 62 (5.8%) 30 (7.3%) 93 (6.3%)
Regarding the geographic distribution of these patients,
we found that there was no diﬀerence in the percentage
of patients undergoing unnecessary tests in high- or low-
volume centers, including universities and nonuniversity
centers, or among the various regions of Italy.
4. Discussion
The purpose of the guidelines in general and, therefore, also
of the EAU and AUA guidelines is not to be prescriptive as to
how a clinician should treat a patient, but rather to provide a
guide and an authoritative reference on the most appropriate
clinical pathway currently available.
Clinical practice guidelines are considered good tools for
controlling and improving the eﬀectiveness and eﬃciency of
medical care [10]. However, it is a common concern that
the publication of guidelines does not necessarily influence
clinical practice. Passive dissemination is generally ineﬀective
in changing physicians’ behavior [11].
The data gathered in the course of our work are
impressive: over 50% of patients underwent unnecessary T
and N-staging and over 70% received unnecessary imaging
for M-staging and we tried to analyze the reasons for this.
In literature, there are only few articles that examine
the usage rate of various imaging modalities in patients
diagnosed with prostate cancer, and to our knowledge all
articles are related to American people [5–9].
In an analysis of the CaPSURE database, Cooperberg et
al. reported that after 1997, 23% of low-risk prostate cancer
patients received some form of imaging staging test [5].
In a more recent paper, Lavery et al. found that nearly
half of low-risk patients underwent imaging that was not
recommended by evidence-based guidelines [6].
A deeper analysis conducted by Choi et al. shows a
widespread overuse of imaging for low-risk prostate and also
a significant geographic variation in use. In particular, men
living in areas of greater income were more likely to undergo
imaging for low risk disease. They suggest this may be a
result of increased patient demand, better access to imaging
modalities, and more generous supplemental insurance [7].
Speculating on the reasons why the guidelines are not
followed or only partially followed, even in important
referral centers, one could argue that in Italy many urologists
do not believe that guidelines, even if based on evidence
and generated by an authoritative source, are actually able to
reflect patients’ individual situations. In literature, there are
two references that go “head to head” in assessing the quality
of the guidelines and their relevance for improving health
[12–14]. Grol et al. argue that even when evidence is avail-
able, the final recommendation often reflects the personal
opinions, local culture, or vested interests of the guideline
developers [12]. On the other hand, Grol et al. aﬃrm that
guidelines are a repository of information for the clinician,
recommending the use of treatments that have been proven
eﬀective and not using treatments that are ineﬀective and
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Table 3: Preoperative imaging staging among patients who could avoid it.
Gleason ≤ 6; PSA ≤ 20 (n = 1063) Gleason 7; PSA ≤ 20 (415) Gleason ≤ 7; PSA ≤ 20 (1478)
T-staging: 567 (53.34%) 238 (57.35%) 805 (54.76%)
CT 514 (90.8%) 213 (89.50%) 727 (90.31%)
eMRI 26 (4.5%) 8 (3.36%) 34 (4.22%)
MRI 26 (4.5%) 14 (5.88%) 40 (4.97%)
CT+MRI 1 (0.2%) 1 (0.42%) 2 (0.25%)
CT+eMRI 0 1 (0.42%) 1 (0.12%)
MRI+eMRI 0 1 (0.42%) 1 (0.12%)
N-staging: 545 (51.27%) 244 (58.80%) 789 (53.67%)
CT 499 (91.5%) 209 (85.66%) 708 (89.73%)
MRI 25 (4.6%) 14 (5.74%) 39 (4.94%)
PET 20 (3.7%) 14 (5.74%) 34 (4.31%)
CT+PET 1 (0.2%) 5 (2.04%) 6 (0.76%)
MRI+PET 0 1 (0.41%) 1 (0.13%)
CT+MRI 0 1 (0.41%) 1 (0.13%)
M-staging: 757 (71.21%) 322 (77.60%) 1079 (73.40%)
Bone scan 757 (100%) 100% 100%
MRI
Others
eMRI
Not doneTC
T-staging
(a)
PET
MRI
Others
CT
N-staging
Not done
(b)
Not done
Bone scan
M-staging
(c)
Figure 1: Proportion of patients with Gleason ≤7 and PSA ≤20 that underwent each examination.
may be harmful [12]. In an article of Briganti et al. on
the external validation of the currently available guidelines
concerning the need to perform a bone scan in patients
with newly diagnosed prostate cancer, it is concluded that
guidelines are mainly based on limited, noncontemporary
studies and that none of the studies and guidelines have yet
been externally validated [15]. Defensive medicine is perhaps
another reason whymany urologists in Italy do not follow the
guidelines for prostate cancer regarding preoperative tests.
Defensive medicine is commonly defined as the ordering of
treatments, tests, and procedures primarily to help protect
the physician from liability rather than to substantially
further the patient’s diagnosis or treatment [16, 17]. While
perhaps not “unnecessary” care, defensive medicine is meant
to oﬀer economic and psychological benefits to the physician
rather than to the patient.
Defensive medicine may supplement care (e.g., addi-
tional testing or treatment), replace care (e.g., referral to
another physician or health facility), or reduce care (e.g.,
refusal to treat particular patients). Some practices, herein
termed assurance behavior (sometimes called “positive”
defensive medicine), involve supplying additional services
of marginal or no medical value with the aim of reducing
adverse outcomes, deterring patients from filing malpractice
claims, or persuading the legal system that the standard
of care was met. Other practices, herein termed avoidance
behavior (sometimes called “negative” defensive medicine),
reflect physicians’ eﬀorts to distance themselves from sources
of legal risk [18]. In our case, it is especially the first type of
defensive medicine that comes to the fore, and it seems to us
that this is not merely wasteful, but that such practices may
also reduce access to care for other patients.
Another explanation for noncompliance with guidelines
could also be that the guidelines are not popular and not
largely adopted in Italy. Urologists probably know that
such guidelines exist, but in everyday practice they are not
consulted, probably due to limited time and pressure of
work, so that guidelines do not enter into common clinical
practice.
A further cause of noncompliance could be the inclusion
of patients in clinical trials that prescribe other, additional
testing. At the time of the enrollment, all the centers taking
part in the study declared that they had no other ongoing
trials.
Further, it may be that some doctors tend to prescribe
a great number of tests even when these are not strictly
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Table 4: Diﬀerence in the use by Italian urologists of imaging
procedures for TNM staging between EAU and AUA guidelines (P
value calculated by chi-square Test).
Gleason 7;
PSA ≤ 20
Gleason ≤ 7;
PSA ≤ 20 Chi Square Test
Number of Patients 415 1470
T-staging 238 805
P value: N.S.
CT 213 727
eMRI 8 34
MRI 14 40
CT+MRI 1 2
CT+eMRI 1 1
MRI+eMRI 1 1
N-staging 244 789
P value: N.S.
CT 209 708
MRI 14 39
PET 14 34
CT+PET 5 6
MRI+PET 1 1
CT+MRI 1 1
M-staging 322 1079
P value: N.S.
BONE SCAN 322 1079
necessary, in order to reassure the patient and to establish a
doctor-patient relationship that in their opinion seems more
solid.
Finally, another explanation could be a conflict of inter-
est. In other countries, physicians may benefit financially
from ordering more bone scans or CT scans, particularly
if they have ownership interests in imaging centers or own
their own CT scans. However, with the way the health
system is structured in Italy, there should be no conflict
of interest because most hospitals are public, and the
physician prescribing or performing the tests does not receive
compensation directly from the patient or according to the
number of such tests.
Last but not least, the present study was not designed
to calculate the additional costs that can result from unnec-
essary diagnostic workups, but it appears undeniable that
prescribing unnecessary costly examinations such as a CT or
a bone scan increases the financial burden on the national
health system. Moreover, the problem of health costs in
Italy is quite complex because each region has diﬀerent
pricing guidelines and the cost of each examination or test
will usually vary from region to region. The value given is,
therefore, an average based on the result of our inquiries. The
complete abdominal CT with contrast medium costs 263,40
euros, the complete abdominal MRI with contrast medium
costs 505,70 euros and the average cost of a total body PET
is 1053,55 euros. Finally, a bone scan has an average cost of
“only” 59 euros for each patient.
This is a prospective study which enrolled only patients
undergoing radical prostatectomy and, therefore, we do not
have information about the diagnostic pathway of patients
undergoing other forms of therapy or active surveillance.
The lack of a central review of the slides could be seen
as another limitation. For this reason, all the data entered
in the e-CRF were assumed to be valid, including the biopsy
Gleason score of 4-5 which is no longer considered valid in
many countries.
5. Conclusions
The MIRROR study shows that the international guidelines
are at present only partially observed by Italian urologists.
The important eﬀect of this is an unnecessary and inap-
propriate increase in cost of care, radiation exposure, and,
possibly, unnecessary anxiety for the patients. The reasons
for noncompliance may vary, but they should be a matter
for study and reflection by the oﬃce boards of scientific
urological associations.
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